Alkem Laboratories539523Leadership appointment or
Dr. Amrut Naik appointed CEO and Key Managerial Personnel with effect from 11 November 2026
Board appointed Dr. Amrut Naik as Chief Executive Officer (CEO) and Key Managerial Personnel.
By ScoutQuest · · 1 min read
- Effective Date
- 11 November 2026
- Board Meeting Date
- 3 November 2026
- Appointee Experience
- 26+ years of global pharma experience
What was announced
- The Board of Directors, at its meeting held on 3 November 2026, appointed Dr. Amrut Naik as the Chief Executive Officer (CEO) and Key Managerial Personnel of the Company.
- The appointment takes effect from 11 November 2026.
- It followed the recommendation of the Nomination and Remuneration Committee.
Who is Dr. Amrut Naik
- Described in the update as a seasoned global pharmaceutical business leader with 26+ years of hands-on experience in building, scaling and transforming global businesses.
- His experience covers Branded Formulations, Generics, APIs, Biologics, Vaccines, Specialty and Innovation-led portfolios.
- Qualifications: a Ph.D. (Tech) in Pharmacology, a Master's in Pharmaceutical Science and a Bachelor's in Pharmaceutical Science.
Term and other details
- Term of appointment: the contract runs for as long as he is in employment of the Company.
- On relationships between directors, the update records NA.
Why this matters to a retail investor
- The CEO is a Key Managerial Personnel, a senior executive role responsible for the day-to-day running of the business.
- A change at the top is a management development that can influence how a company's strategy is executed over time; the update sets out the appointment, the effective date, the term and the appointee's background.
- How this plays out for the business would depend on the company's plans under the new CEO, which this update does not set out.
Also from Alkem Laboratories
Alkem Laboratories to hold Q2 and H1FY27 earnings conference call on November 12, 2026, hosted by Motilal Oswal Securities
4 Nov 2026
Alkem Laboratories to host Q2FY27 and H1FY27 earnings conference call on November 12, 2026
4 Nov 2026
Board meeting on 12th November, 2026 to approve Q2 and H1 results
4 Nov 2026
More numbers
- Experience of the appointee26+ years
Source: BSE · 3 Nov 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.